Rationale for combination use of targeted agents in ovarian cancer: do we have one?
Coleman
Robert L
RL
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. rcoleman@mdanderson.org
Kohn
Elise C
EC
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D043823:Taxoids; D000077143:Docetaxel; D000068877:Imatinib Mesylate